Stereochemistry | ABSOLUTE |
Molecular Formula | C22H19Br2NO3 |
Molecular Weight | 505.199 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1(C)[C@@H](C=C(Br)Br)[C@H]1C(=O)O[C@H](C#N)C2=CC(OC3=CC=CC=C3)=CC=C2
InChI
InChIKey=OWZREIFADZCYQD-NSHGMRRFSA-N
InChI=1S/C22H19Br2NO3/c1-22(2)17(12-19(23)24)20(22)21(26)28-18(13-25)14-7-6-10-16(11-14)27-15-8-4-3-5-9-15/h3-12,17-18,20H,1-2H3/t17-,18+,20-/m0/s1
Molecular Formula | C22H19Br2NO3 |
Molecular Weight | 505.199 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Deltamethrin (DLM) is a pyrethroid insecticide and veterinary treatment that is approved for use in the EU, Australia and the USA. It has a low aqueous solubility, is semi-volatile and has a low potential to leach to groundwater. It is not persistent in soil and is non-mobile. Deltamethrin is highly toxic to humans and other mammals and is a neurotoxin. It is relatively non-toxic to birds and earthworms although it presents a high risk to most aquatic organisms and honeybees. Recent in vitro and in vivo studies have shown that the deltamethrin have the potential to induce apoptogenic signaling pathways which plays an important role in the mechanism of anticancer action. Thus, deltamethrin thereof could have the potential to develop as an anticancer agent.
CNS Activity
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Female BALB/c mice received deltamethrin in two daily oral doses; 6 mg/kg for 84 days and 15 mg/kg for 14 days.
Route of Administration:
Oral
DLM (10–50 uM) induced apoptosis in both murine thymocytes and splenocytes via activating mitochondrial caspase dependent signaling pathways.
DLM (>100 uM) increased the Ca2+ level and caused apoptosis in normal rat neural cells. DLM at
low concentration (5–10 uM) induced calcium dependent apoptogenic
signaling pathways in OC2 human oral cancer cells.